Abstract: Methods of detecting an analyte in a sample are provided. In one embodiment, the method comprises forming a partition comprising the sample, a binding agent capable of emitting a signal when bound to the analyte, and a marker capable of identifying the partition; allowing the binding agent to bind to the analyte, if present; and detecting the presence of the analyte in the sample by detecting the signal emitted from the binding agent in the partition.
Abstract: A concentrated sample having enhanced concentration of the one or more different populations of target rare molecules is incubated with, for each different population of target rare molecules, a particulate or non-particulate affinity agent that comprises a specific binding partner that is specific for and binds to a target rare molecule. The affinity agent comprises a mass spectrometry (MS) label precursor or a first alteration agent, which either facilitates the formation of an MS label from the MS label precursor or releases an entity that comprises the MS label precursor from the affinity agent. The MS label corresponds to one of the populations of target rare molecules. A second alteration agent is employed if the first alteration agent does not facilitate the formation of an MS label from the MS label precursor. MS analysis is used to determine each different MS label.
Type:
Grant
Filed:
May 29, 2015
Date of Patent:
October 20, 2020
Assignee:
Siemens Healthcare Diagnostics Inc.
Inventors:
Michael Pugia, Julia Philip, Karen Marfurt
Abstract: A point of care immunization system based upon microfluidics and microtitration technologies to rapidly test a patient in order to ascertain an immunization profile so that vaccinations can be administered to address identified gaps. A point of care system comprised of uniquely shaped and color distinguishing sample and test cartridges, with said test cartridges configured to meet healthcare requirements of national governing bodies. A point of care system including an easy access vaccine storage device with indicators to provide data on viability of stored vaccines.
Abstract: Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Particularly preferred kits include those with a minimum number of food preparations that have an average discriminatory p-value of ?0.07 as determined by their raw p-value or an average discriminatory p-value of ?0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.
Type:
Grant
Filed:
April 16, 2019
Date of Patent:
September 29, 2020
Assignee:
Biomerica, Inc.
Inventors:
Elisabeth Laderman, Zackary Irani-Cohen
Abstract: The invention relates to the use of recombinant/semi-synthetic nucleosomes carrying histone and/or DNA modifications as a reference standard for quantification of covalently modified (on the histone proteins or wrapping DNA), variant, or mutant nucleosomes (collectively “modified nucleosomes” or “nucleosome modifications”) from a biological sample. The invention further relates to methods of using the assay to accurately quantify single or combinatorial nucleosome modifications as biomarkers of disease.
Type:
Grant
Filed:
November 8, 2019
Date of Patent:
September 29, 2020
Assignee:
EpiCypher, Inc.
Inventors:
Martis William Cowles, Matthew F. Whelihan, Andrea L. Johnstone, Michael-Christopher Koegh, Zu-Wen Sun, Nathan W. Hall, Matthew R. Marunde
Abstract: Provided is a method for quantitative analysis of a sample. The method includes steps of (a) providing a singular marker representative of one or more features of the sample, the sample comprising a population of individual units of the marker; (b) measuring the marker with dot blot analysis, wherein the quantitation result is an absolute amount of the marker's population of individual units in the sample, normalized by the sample volume or by the sample weight; and (c) obtaining an objective determination of the one or more features of the sample based on the quantitation result of the marker. Also disclosed is a reference database and a method to use the reference database for diagnosing cancer in a patient.
Abstract: A fluidic device includes: a circulation flow path; and a capture part arranged on the circulation flow path and configured to capture a sample substance in a solution and/or a detection part arranged on the circulation flow path and configured to detect a sample substance in a solution.
Type:
Grant
Filed:
August 17, 2017
Date of Patent:
September 15, 2020
Assignees:
The University of Tokyo, NIKON CORPORATION
Abstract: The present invention deals with a method for detecting a protein in a protein sample by amplifying and enhancing small differences between proteins contained in the protein sample. In particular, the present invention uses a cascade of enzymatic modification steps to detect and identify a protein in a protein sample by enhancing small differences between the protein and other proteins contained in the protein sample. Further, the present invention provides a method for distinguishing two proteins having substantially identical or similar amino acid sequences but different protein conformations.
Abstract: The present invention relates to a method for detecting and measuring the presence of cell free mono-nucleosomes and oligo-nucleosomes that contain histone H1 or a histone H1 modification, variant or isoform, and the use of such measurements for the detection and diagnosis of disease.
Type:
Grant
Filed:
October 21, 2016
Date of Patent:
September 8, 2020
Assignee:
Belgian Volition SPRL
Inventors:
Mark Edward Eccleston, Jacob Vincent Micallef
Abstract: Herein is reported a method for the detection of free antigen of a multispecific antibody in a sample, whereby the antigen to be detected can be specifically bound by a first binding site of the multispecific antibody, comprising the step of incubating a sample comprising free antigen and multispecific antibody with an anti-idiotypic antibody, which specifically binds to a second binding specificity of the bispecific antibody, which is different from the first binding specificity, whereby the anti-idiotypic antibody is bound to a solid phase.
Abstract: Disclosed herein are methods for detecting protein expression in an individual diagnosed with cystic fibrosis. The methods, in certain aspects, include the steps of obtaining a sample from said individual and detecting expression in said sample of each protein of a protein set. The method may further include the step of determining expression level of one or more proteins of the protein set. The disclosed methods may be used to predict one or more clinical parameters in an individual having cystic fibrosis.
Type:
Grant
Filed:
March 21, 2018
Date of Patent:
September 1, 2020
Assignee:
Children's Hospital Medical Center
Inventors:
Assem Ziady, Rhonda Szczesniak, John Clancy, Cole Brokamp
Abstract: Provided is a method for detecting a specific protein, having excellent reliability. The method is characterized by including a mass spectrometry step of detecting the specific protein by mass spectrometry and an immunoassay step of detecting the specific protein by immunoassay using an anti-peptide antibody specifically bonded to the specific protein.
Type:
Grant
Filed:
November 4, 2016
Date of Patent:
August 25, 2020
Assignee:
Morinaga Institute of Biological Science, Inc.
Abstract: The present invention relates to methods for identifying markers for systemic lupus erythematosus (SLE) and to the markers identified with the aid of this method, which can differentiate between SLE and other autoimmune diseases on the one hand and between different SLE subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control in SLE. The invention also relates to methods for screening and validating active substances for application in SLE subgroups.
Type:
Grant
Filed:
February 10, 2015
Date of Patent:
August 18, 2020
Assignee:
Oncimmune Germany GmbH
Inventors:
Angelika Lüking, Peter Schulz-Knappe, Carmen Theek, Petra Budde, Anna Telaar
Abstract: The present invention relates to the use of a histone H1 binding agent for detecting, isolating and/or purifying cell free nucleosomes of tumor origin from a biological sample. The invention also describes methods of negative or positive selection using histone H1 binding agents, in order to enrich a sample for cell free nucleosomes of tumor origin.
Type:
Grant
Filed:
October 21, 2016
Date of Patent:
August 18, 2020
Assignee:
Belgian Volition SPRL
Inventors:
Mark Edward Eccleston, Jacob Vincent Micallef
Abstract: This invention provides methods for treating diseases associated with elevated p38 mitogen-activated protein kinase activity. Moreover, the invention provides methods for testing a candidate compound for a p38 mitogen-activated protein kinase modifying activity by calculating the level of relocalization of an SMN complex component from the cytoplasm to the nucleus of a cell. Additionally, the invention provides a kit and a system for calculating the same.
Type:
Grant
Filed:
March 26, 2018
Date of Patent:
August 11, 2020
Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Abstract: A bioassay for the detection of multiple target analytes that includes living immunocytes of a plurality of predetermined types; a signal-generating reporter within each immunocyte that is responsive to predetermined changes occurring within the immunocyte and that includes a bioluminescent protein linked to a fluorescent protein; a signal transduction pathway associated with each signal-generating reporter that is operative to induce the predetermined changes within each immunocyte; a detector element associated with the signal transduction pathway that is operative to trigger the signal transduction pathway; an analyte binding element associated with the detector element that is specific to both the detector element and a target analyte; and wherein upon the binding of an analyte binding element to which a target analyte is also bound to the detector element, the detector element triggers the signal transduction pathway causing the predetermined changes to occur within the living biological cell, thereby ca
Type:
Grant
Filed:
August 20, 2018
Date of Patent:
August 11, 2020
Assignee:
Fundamental Solutions Corporation
Inventors:
M. Russell Williams, Joel Lwande, Shengwen Liang, Kyle McQuaid
Abstract: The present invention is directed to novel assays for detecting target molecules. The assays employ small size, detectably labeled, magnetic nanoparticles associated with a capture molecule. The detection assay is accelerated by applying magnetic field during the assay. The assays of the invention can be used to enhance the efficiency of the detection step in dot blot, Western blot and ELISA.
Abstract: The present invention is comprised in the field of glycobiology. In particular, it relates to a method for separating, in biological samples, the fraction bound to or associated with sulfated glycosaminoglycans (GAGs), and the applications thereof in biomedicine, such as for identifying the profile of glycoproteins or the profile of lipids bound to or associated with sulfated GAGs, detecting an alteration in the pattern of glycosylation by sulfated GAGs, identifying biomarkers for the diagnosis, for the prognosis, for monitoring the progression of a disease or of the effect of a therapy, or for identifying compounds suitable for the treatment of a disease. The invention also relates to methods for diagnosing mucopolysaccharidosis and for diagnosing and determining the prognosis of a kidney disease.
Type:
Grant
Filed:
September 9, 2016
Date of Patent:
July 28, 2020
Assignees:
SERVIZO GALEGO DE SAUDE (SERGAS), UNIVERSIDADE DE SANTIAGO DE COMPOSTELA, FUNDACIÓN INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA
Inventors:
Manuela Alonso Sampedro, Victor Álvarez González, Cristóbal Colón Mejeras, Miguel A. García González, Olaya Lamas González
Abstract: Disclosed is a method for detecting a test substance, including a first contact step of bringing the test substance, a capturing body 1 that has binding properties to the test substance and is fixed to a substrate, and a capturing body 2 that has binding properties to the test substance and contains a label into contact with each other in a liquid to arrange at least a part of the capturing body 2 on the substrate; after the first contact step, a first dissociation step of dissociating a part of substances containing the capturing body 2 from the substrate and releasing it into the liquid; after the first dissociation step, a second contact step of bringing the test substance, the capturing body 1 that has binding properties to the test substance and is fixed to a substrate, and the capturing body 2 that has binding properties to the test substance and contains a label into contact with each other in the liquid to arrange at least a part of the capturing body 2 on the substrate; after the second contact step,
Abstract: Platform technology involving aqueous microdroplet reaction vessels created, arrayed, and characterized by imaging microscopy in a microfluidic device are applied to a wide variety of bioassays involving the detection and phenotypic characterization of single cells. The bioassays include the rapid and automated detection of microbial pathogens and their antibiotic sensitivity from patient samples as well as the characterization of immune responses using a patient's own cells, including the killing of tumor cells.